Breakdown | |||||
TTM | Mar 2024 | Mar 2023 | Dec 2020 | Dec 2019 | Dec 2018 |
---|---|---|---|---|---|
Income Statement | Total Revenue | ||||
16.25M | 5.83M | -105.40M | 101.98M | 60.29M | 79.47M | Gross Profit |
3.41M | -89.30M | -150.93M | 81.20M | 60.29M | 75.80M | EBIT |
-65.22M | -2.74B | -253.17M | -47.41M | -135.38M | 41.44M | EBITDA |
23.38M | -2.74B | -234.09M | -13.81M | -135.05M | 41.68M | Net Income Common Stockholders |
-547.80M | -2.66B | -130.98M | -58.04M | -334.04M | -5.01M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
7.98M | 7.98M | 8.73M | 12.49M | 17.55M | 3.54M | Total Assets |
368.50M | 368.50M | 2.91B | 2.82B | 2.68B | 2.08B | Total Debt |
120.50M | 2.20M | 52.13M | 180.08M | 321.80M | 378.12M | Net Debt |
112.53M | -5.78M | 43.40M | 167.59M | 304.25M | 374.58M | Total Liabilities |
309.57M | 3.00K | 1.02B | 282.84M | 441.08M | 690.86M | Stockholders Equity |
-234.35M | 368.50M | 1.93B | 2.53B | 563.97M | 320.46M |
Cash Flow | Free Cash Flow | ||||
-51.86M | -59.98M | -97.19M | -57.23M | -54.17M | 17.44M | Operating Cash Flow |
-50.12M | -58.22M | -95.12M | -54.01M | -51.19M | 17.81M | Investing Cash Flow |
29.48M | 44.06M | 63.02M | -5.98M | 70.44M | 141.54M | Financing Cash Flow |
23.02M | 12.59M | -34.46M | 43.86M | -5.24M | -156.36M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
64 Neutral | $12.67B | 9.74 | 7.58% | 17015.08% | 12.21% | -6.96% | |
52 Neutral | $40.05M | ― | -8.01% | ― | 38.38% | 71.72% | |
52 Neutral | $47.06M | ― | -8.58% | 7.79% | 678.57% | 98.81% | |
46 Neutral | $13.16M | ― | ― | ― | ― | ||
44 Neutral | $3.98M | ― | -5013.15% | ― | -57.33% | -27.24% | |
41 Neutral | $39.02M | ― | -11.19% | ― | -13.79% | 62.04% | |
34 Underperform | $2.93M | ― | -538.85% | ― | 78.84% | 97.65% |
On April 21, 2025, Beneficient completed a primary capital transaction involving a limited partner interest in an investment fund valued at $233,333. The transaction involved the issuance of Series B-7 Resettable Convertible Preferred Stock, convertible into Class A Common Stock, enhancing the collateral for Beneficient’s ExAlt loan portfolio. This marks Beneficient’s second GP Primary transaction of the fiscal year, reflecting its strategic focus on liquidity and primary capital solutions. The transaction is expected to increase the company’s tangible book value and aligns with its growth objectives, aiming to meet the substantial demand for primary commitments in the alternative asset market.
Spark’s Take on BENF Stock
According to Spark, TipRanks’ AI Analyst, BENF is a Underperform.
Beneficient’s overall stock score is low, primarily due to weak financial performance characterized by operational losses, solvency issues, and negative cash flow trends. Despite some positive developments in earnings and corporate events, the technical indicators and valuation remain unfavorable.
To see Spark’s full report on BENF stock, click here.
On April 4, 2025, Beneficient closed a $9.6 million primary capital transaction with Pulse Pioneer Fund, LP, marking its first GP Primary transaction of the fiscal year. This transaction, involving the issuance of Series B-6 Resettable Convertible Preferred Stock, is expected to enhance the collateral for Beneficient’s ExAlt loan portfolio by approximately $9.6 million. The company believes this move will drive shareholder value and support its strategic vision and growth objectives, as it continues to address the significant demand for primary commitments in the alternative asset market.
On March 10, 2025, Beneficient announced a binding agreement to settle all claims in the GWG Litigation, which involved lawsuits in federal and bankruptcy courts in Texas against the company and its directors. The settlement, pending court approval, resolves claims without admission of fault and will be funded by insurance. This move aims to eliminate litigation costs and allow the company to focus on its business strategy, although other related claims remain outstanding.